Summary
Important therapeutic principles were established in developing effective enzyme replacement therapy for patients with Gaucher disease. The background and sequence of the investigations that led to effective delivery of exogenous glucocerebrosidase to the lipid-storing macrophages in patients with Guacher disease are described. The principle of targeting the intravenously injected enzyme to the mannose lectin on the surface of these cells by engineering the glycoform of the enzyme is a useful model of an essential requirement for effective enzyme therapy. Similar strategies are expected to be effective for the treatment of a number of hereditary metabolic disorders of humans.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Barton NW, Furbish FS, Murray FJ, Garfield M, Brady RO (1990) Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.Proc Natl Acad Sci USA 87: 1913–1916.
Barton NW, Brady RO, Dambrosia JM et al (1991) Replacement therapy for inherited enzyme deficiency — macrophage-targeted glucocerebrosidase for Gaucher's disease.N Engl J Med 324: 1464–1470.
Barton NW, Brady RO, Dambrosia JM et al (1992) Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher's disease.J Pediatr 120: 177–180.
Beutler E, Kay A, Saven A et al (1991) Enzyme replacement therapy for Gaucher disease.Blood 78: 1183–1189.
Brady RO (1966) The sphingolipidoses.N Engl J Med 275: 312–318.
Brady RO (1984) Enzyme replacement in the sphingolipidoses. In Barranger JA, Brady RO, eds.Molecular Basis of Lysosomal Storage Disorders, Orlando: Academic Press, 461–478.
Brady RO, Furbish FS (1982) Enzyme replacement therapy: specific targeting of exogenous enzymes to storage cells. In Martonosi AN, ed.Membranes and Transport, Vol 2. New York: Plenum Press, 587–592.
Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS (1974) Replacement therapy for inherited enzyme deficiency: use of purified glucocerebrosidase in Gaucher's disease.N Engl J Med 291: 989–993.
Brady RO, Pentchev PG, Gal AE et al (1976) Enzyme replacement therapy for the sphinoglipidoses. In Volk BW, Schneck L, eds.Current Trends in the Sphingolipidoses and Allied Disorders. New York: Plenum Press, 523–532.
Dale GL, Villacorte DG, Beutler E (1976) Solubilization of glucocerebrosidase from human placenta and demonstration of a phospholipid requirement for its catalytic activity.Biochem Biophys Res Commun 71: 1048–1053.
Doebber TW, Wu MS, Bugianesi RL et al (1982) Enhanced macrophage uptake of synthetically glycosylated human placental β-glucocerebrosidase.J Biol Chem 257: 2193–2199.
Fallet S, Grace ME, Sibille A et al (1992) Enzyme augmentation in moderate to life-threatening Gaucher disease.Pediatr Res 31: 496–502.
Fidler IJ, Sone S, Folger WE, Barnes Z (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.Proc Natl Acad Sci USA 78: 1680–1684.
Furbish FS, Blair HE, Shiloach J, Pentchev PG, Brady RO (1977) Enzyme replacement therapy in Gaucher's disease: large-scale purification of glucocerebrosidase suitable for human administration.Proc Natl Acad Sci USA 74: 3560–3563.
Furbish FS, Steer CJ, Barranger JA, Jones EA, Brady RO (1978) The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells.Biochem Biophys Res Commun 149: 1047–1053.
Furbish FS, Steer CJ, Krett NL, Barranger JA (1981) Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation.Biochim Biophys Acta 673: 425–434.
Furbish FS, Oliver KL, Zirzow GC, Brady RO, Barranger JA (1984) Interaction of human placental glucocerebrosidase with hepatic lectins. In Barranger JA, Brady RO, eds.The Molecular Basis of Lysosomal Storage Disorders. Orlando: Academic Press, 219–232.
Grabowski GA, Pastores G, Brady RO, Barton NW (1992) Safety and efficacy of macrophage-targeted recombinant glucocerebrosidase therapy.Clin Res 41: 390a.
Mistry PK, Davis S, Corfield A, Dixon AK, Cox TM (1992) Successful treatment of bone marrow failure in Gaucher's disease with low-dose modified glucocerebrosidase.Q J Med New Series 84: 541–546.
Murray GJ (1987) Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells. In Green R, Widder KJ, eds. Drug and Enzyme Targeting.Methods Enzymol. 149: 25–42.
Murray GJ, Howard KD, Richards SM, Barton NW, Brady RO (1991) Gaucher's disease: lack of antibody response in 12 patients following repeated intravenous infusions of mannose-terminal glucocerebrosidase.J Immunol Methods 137: 113–120.
Parker RI, Barton NW, Read EJ, Brady RO (1991) Hematologic improvement in a patient with Gaucher's disease on long-term replacement therapy: evidence for decreased splenic sequestration and improved red blood cell survival.Am J Hematol 38: 130–137.
Patterson MC, Horowitz M, Abel RB et al (1993) Isolated horizontal supranuclear gaze palsy as a marker of severe systemic involvement in Gaucher's disease.Neurology 43: 1993–1997.
Pentchev PG, Brady RO, Hibbert SR, Gal AE, Shapiro D (1973) Isolation and characterization of glucocerebrosidase from human placental tissue.J Biol Chem 248: 5256–5261.
Pentchev PG, Barranger JA, Gal AE, Furbish FS, Brady RO (1978) Incorporation of exogenous enzymes into lysosomes. A theoretical and practical means for correcting lysosomal blockage. In Walborg EF Jr, ed.Glycoproteins and Glycolipids in Disease Processes. ACS Symposium Series, 80. Washington: ACS, 150–159.
Richards SM, Olson TA, McPherson JM (1993) Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase.Blood 82: 1402–1409.
Stahl PD, Rodman JS, Miller MJ, Schlesinger PH (1978) Evidence for receptor-mediated binding of glycoproteins and lysosomal glycosidases by alveolar macrophages.Proc Natl Acad Sci USA 75: 1399–1430.
Takasaki S, Murray GJ, Furbish FS, Brady RO, Barranger JA, Kobata A (1984) Structure of theN-asparagine-linked oligosaccharide units of human placental β-glucocerebrosidase.J Biol Chem 259: 10112–10117.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brady, R.O., Murray, G.J. & Barton, N.W. Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease. J Inherit Metab Dis 17, 510–519 (1994). https://doi.org/10.1007/BF00711365
Issue Date:
DOI: https://doi.org/10.1007/BF00711365